國立虎尾科技大學 |

Rethinking platinum anticancer drug design = towards targeted and immuno-chemotherapeutic approaches /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Rethinking platinum anticancer drug design/ by Daniel Yuan Qiang Wong.
其他題名:	towards targeted and immuno-chemotherapeutic approaches /
作者:	Wong, Daniel Yuan Qiang.
出版者:	Singapore :Springer Singapore : : 2018.,
面頁冊數:	xxx, 147 p. :ill. (some col.), digital ; : 24 cm.;
Contained By:	Springer eBooks
標題:	Cancer - Chemotherapy. -
電子資源:	http://dx.doi.org/10.1007/978-981-10-8594-9
ISBN:	9789811085949

Rethinking platinum anticancer drug design = towards targeted and immuno-chemotherapeutic approaches /
Wong, Daniel Yuan Qiang.

Rethinking platinum anticancer drug designtowards targeted and immuno-chemotherapeutic approaches /[electronic resource] :by Daniel Yuan Qiang Wong. - Singapore :Springer Singapore :2018. - xxx, 147 p. :ill. (some col.), digital ;24 cm. - Springer theses,2190-5053. - Springer theses..

Introduction- Cisplatin- Now and Future -- Harnessing Chemoselective Imine Ligation for Tethering Bioactive Molecules to Platinum (IV) Prodrugs -- Probing the Platinum(IV) Prodrug Hypothesis - Are Platinum(IV) Complexes Really Prodrugs of Cisplatin? -- Induction of Targeted Necrosis with HER2-Targeted Platinum(IV) Anticancer Prodrugs -- Immuno-Chemotherapeutic Platinum(IV) Prodrugs of Cisplatin as Multimodal Anticancer Agents -- Induction of Immunogenic Cell Death by Chemotherapeutic Platinum Complexes -- Concluding Remarks.

This thesis describes the authors' pioneering efforts in the conceptualization and implementation of combined platinum-based immuno-chemotherapeutics, which represent a significant paradigm shift from the conventional approach of directly targeting cancer. The work described has opened up a rich and largely unexplored area for platinum-based drug design, and ultimately paves the way for superior immuno-chemotherapeutics with better clinical outcome for patients. Historically, the contribution of the immune system to chemotherapy outcomes has been neglected, as anticancer drugs were believed to be immunosuppressive. However, this has been challenged by contemporary evidence suggesting that many chemotherapeutics, including platinum-based agents, stimulate the innate and/or adaptive immune system and that these "secret allies" contribute tangibly to clinical outcomes. A multi-pronged immuno-chemotherapeutic approach not only shrinks tumors, but more importantly, reactivate dormant immune responses to malignancies, eliminating residual cancer cells.

ISBN: 9789811085949

Standard No.: 10.1007/978-981-10-8594-9doiSubjects--Topical Terms:

645264
Cancer
--Chemotherapy.

LC Class. No.: RC271.C5 / W664 2018

Dewey Class. No.: 616.994061

Rethinking platinum anticancer drug design = towards targeted and immuno-chemotherapeutic approaches /
LDR:02664nam a2200325 a 4500 001 926908
003 DE-He213
005 20181228155706.0
006 m d
007 cr nn 008maaau
008 190626s2018 si s 0 eng d
020 $a 9789811085949 $q (electronic bk.)
020 $a 9789811085932 $q (paper)
024 7 $a 10.1007/978-981-10-8594-9 $2 doi
035 $a 978-981-10-8594-9
040 $a GP $c GP
041 0 $a eng
050 4 $a RC271.C5 $b W664 2018
072 7 $a PSB $2 bicssc
072 7 $a SCI013020 $2 bisacsh
082 0 4 $a 616.994061 $2 23
090 $a RC271.C5 $b W872 2018
100 1 $a Wong, Daniel Yuan Qiang. $3 1205863
245 1 0 $a Rethinking platinum anticancer drug design $h [electronic resource] : $b towards targeted and immuno-chemotherapeutic approaches / $c by Daniel Yuan Qiang Wong.
260 $a Singapore : $c 2018. $b Springer Singapore : $b Imprint: Springer,
300 $a xxx, 147 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Springer theses, $x 2190-5053
505 0 $a Introduction- Cisplatin- Now and Future -- Harnessing Chemoselective Imine Ligation for Tethering Bioactive Molecules to Platinum (IV) Prodrugs -- Probing the Platinum(IV) Prodrug Hypothesis - Are Platinum(IV) Complexes Really Prodrugs of Cisplatin? -- Induction of Targeted Necrosis with HER2-Targeted Platinum(IV) Anticancer Prodrugs -- Immuno-Chemotherapeutic Platinum(IV) Prodrugs of Cisplatin as Multimodal Anticancer Agents -- Induction of Immunogenic Cell Death by Chemotherapeutic Platinum Complexes -- Concluding Remarks.
520 $a This thesis describes the authors' pioneering efforts in the conceptualization and implementation of combined platinum-based immuno-chemotherapeutics, which represent a significant paradigm shift from the conventional approach of directly targeting cancer. The work described has opened up a rich and largely unexplored area for platinum-based drug design, and ultimately paves the way for superior immuno-chemotherapeutics with better clinical outcome for patients. Historically, the contribution of the immune system to chemotherapy outcomes has been neglected, as anticancer drugs were believed to be immunosuppressive. However, this has been challenged by contemporary evidence suggesting that many chemotherapeutics, including platinum-based agents, stimulate the innate and/or adaptive immune system and that these "secret allies" contribute tangibly to clinical outcomes. A multi-pronged immuno-chemotherapeutic approach not only shrinks tumors, but more importantly, reactivate dormant immune responses to malignancies, eliminating residual cancer cells.
650 0 $a Cancer $x Chemotherapy. $3 645264
650 0 $a Platinum $x Therapeutic use. $3 1205864
650 1 4 $a Chemistry. $3 593913
650 2 4 $a Medicinal Chemistry. $3 668872
650 2 4 $a Medical Biochemistry. $3 668897
650 2 4 $a Cancer Research. $3 668358
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
830 0 $a Springer theses. $3 831604
856 4 0 $u http://dx.doi.org/10.1007/978-981-10-8594-9
950 $a Chemistry and Materials Science (Springer-11644)